Mark Purcell
Stock Analyst at Morgan Stanley
(1.41)
# 3,527
Out of 5,048 analysts
6
Total ratings
66.67%
Success rate
-3.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $50.05 | +15.88% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $123.86 | -7.96% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $46.35 | -5.07% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $81.72 | +4.01% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $49.11 | +144.35% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $50.05
Upside: +15.88%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $123.86
Upside: -7.96%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $46.35
Upside: -5.07%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $81.72
Upside: +4.01%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $49.11
Upside: +144.35%